RPG Life Sciences Past Earnings Performance
Past criteria checks 1/6
RPG Life Sciences has been growing earnings at an average annual rate of 24.2%, while the Pharmaceuticals industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 12% per year. RPG Life Sciences's return on equity is 18.6%, and it has net margins of 11.4%.
Key information
24.2%
Earnings growth rate
24.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 12.0% |
| Return on equity | 18.6% |
| Net Margin | 11.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How RPG Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 6,183 | 707 | 1,536 | 0 |
| 30 Jun 24 | 5,997 | 923 | 1,541 | 0 |
| 31 Mar 24 | 5,821 | 877 | 1,542 | 0 |
| 31 Dec 23 | 5,736 | 848 | 1,513 | 0 |
| 30 Sep 23 | 5,505 | 774 | 1,459 | 0 |
| 30 Jun 23 | 5,317 | 715 | 1,403 | 0 |
| 31 Mar 23 | 5,128 | 676 | 1,346 | 0 |
| 31 Dec 22 | 4,981 | 648 | 1,237 | 0 |
| 30 Sep 22 | 4,831 | 603 | 1,209 | 0 |
| 30 Jun 22 | 4,610 | 561 | 1,188 | 0 |
| 31 Mar 22 | 4,402 | 515 | 1,153 | 0 |
| 31 Dec 21 | 4,291 | 509 | 1,058 | 0 |
| 30 Sep 21 | 4,211 | 491 | 1,046 | 0 |
| 30 Jun 21 | 4,056 | 445 | 952 | 0 |
| 31 Mar 21 | 3,891 | 400 | 1,055 | 0 |
| 31 Dec 20 | 3,851 | 361 | 1,080 | 0 |
| 30 Sep 20 | 3,718 | 311 | 1,065 | 0 |
| 30 Jun 20 | 3,732 | 297 | 1,055 | 0 |
| 31 Mar 20 | 3,756 | 290 | 993 | 0 |
| 31 Dec 19 | 3,557 | 276 | 1,010 | 0 |
| 30 Sep 19 | 3,523 | 249 | 1,008 | 0 |
| 30 Jun 19 | 3,443 | 173 | 997 | 0 |
| 31 Mar 19 | 3,302 | 108 | 988 | 0 |
| 31 Dec 18 | 3,448 | 105 | 1,056 | 0 |
| 30 Sep 18 | 3,495 | 107 | 1,048 | 0 |
| 30 Jun 18 | 3,485 | 149 | 1,027 | 0 |
| 31 Mar 18 | 3,440 | 135 | 1,009 | 0 |
| 31 Dec 17 | 3,360 | 141 | 870 | 0 |
| 30 Sep 17 | 3,062 | 97 | 833 | 0 |
| 30 Jun 17 | 2,948 | 62 | 801 | 0 |
| 31 Mar 17 | 2,936 | 121 | 835 | 0 |
| 31 Dec 16 | 3,029 | 229 | 784 | 0 |
| 30 Sep 16 | 3,095 | 270 | 789 | 0 |
| 30 Jun 16 | 2,993 | 194 | 782 | 0 |
| 31 Mar 16 | 2,552 | 84 | 696 | 0 |
| 31 Dec 15 | 2,758 | 141 | 1,040 | 0 |
| 30 Sep 15 | 2,609 | 119 | 966 | 0 |
| 30 Jun 15 | 2,501 | 20 | 978 | 0 |
| 31 Mar 15 | 2,423 | 10 | 686 | 0 |
| 31 Dec 14 | 2,290 | -42 | 928 | 0 |
| 30 Sep 14 | 2,273 | -98 | 1,019 | 0 |
| 30 Jun 14 | 2,312 | -1 | 699 | 0 |
| 31 Mar 14 | 2,356 | 534 | 993 | 0 |
| 31 Dec 13 | 2,400 | 613 | 969 | 0 |
Quality Earnings: 532983 has a large one-off loss of ₹262.4M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: 532983's current net profit margins (11.4%) are lower than last year (14.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 532983's earnings have grown significantly by 24.2% per year over the past 5 years.
Accelerating Growth: 532983's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 532983 had negative earnings growth (-8.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20%).
Return on Equity
High ROE: 532983's Return on Equity (18.6%) is considered low.